Apogee Therapeutics Engages with Investors at Upcoming Conferences
Apogee Therapeutics, Inc. (NASDAQ: APGE), based in San Francisco and Boston, has made significant strides in the biotechnology field. The company has announced its participation in several investor conferences that provide great opportunities to showcase its innovative research and development in immunology.
Schedule of Upcoming Investor Conferences
Apogee Therapeutics has outlined its conference schedule, featuring notable events where management will engage directly with investors:
Guggenheim's 2nd Annual Healthcare Innovation Conference
Scheduled for a Tuesday, the discussions will kick off with a fireside chat at 1:30 p.m. ET. Investors can expect insights into Apogee's advancements and future strategies.
Stifel 2025 Healthcare Conference
This event will take place on Wednesday, featuring a fireside chat at 11:20 a.m. ET, where Apogee will further elaborate on its growth and product pipeline.
TD Cowen Immunology and Inflammation Virtual Summit
On Thursday, Apogee will participate in a virtual summit focusing on immunology, presenting a fireside chat at 12:30 p.m. ET, delving into their innovative approaches.
Jefferies London Healthcare Conference
Next Wednesday, the company will engage with international investors at the Jefferies Conference, with a fireside chat scheduled for 3:00 p.m. GMT / 10:00 a.m. ET.
Citi 2025 Global Healthcare Conference
Wrapping up the conference season, Apogee will present at this event on Wednesday, where their fireside chat will commence at 9:45 a.m. ET.
Webcast Availability
For those unable to attend, Apogee will provide live and archived webcasts of these events on their official website within the Investors section. This initiative opens the door for a wider audience to stay informed about Apogee's developments.
About Apogee Therapeutics
As a clinical-stage biotechnology leader, Apogee Therapeutics is committed to pioneering innovative biologics aimed at addressing major unmet medical needs in immunology. Their portfolio focuses on conditions such as Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD). The firm’s leading program, APG777, aims to revolutionize treatment for AD, emphasizing advancements in antibody engineering to improve therapeutic efficacy.
Apogee's strategic direction is built on a foundation of robust scientific expertise and groundbreaking research, which they believe will yield significant benefits for patients who currently receive inadequate care. Their mission reflects a deep commitment to improving health outcomes in chronic conditions.
Contact Information
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
Frequently Asked Questions
What is the focus of Apogee Therapeutics?
Apogee Therapeutics focuses on advancing biologics targeting immunology, particularly in diseases like Atopic Dermatitis and asthma.
When is the next investor conference for Apogee?
Apogee's next conference is the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, with discussions starting at 1:30 p.m. ET.
How can investors access the conference webcasts?
Investors can access live and archived webcasts through the Investors section on Apogee's official website.
Who should be contacted for investor relations?
Noel Kurdi, the VP of Investor Relations at Apogee, is the key contact for investor inquiries.
What is APG777?
APG777 is Apogee Therapeutics' leading antibody program aimed at treating Atopic Dermatitis, showcasing their innovative research in the immunology sector.